Small vessel disease burden and functional brain connectivity in mild cognitive impairment

Background

The role of small vessel disease in the development of dementia is not yet completely understood. Functional brain connectivity has been shown to differ between individuals with and without cerebral small vessel disease. However, a comprehensive measure of small vessel disease quantifying the overall damage on the brain is not consistently used and studies using such measure in mild cognitive impairment individuals are missing.

Method

Functional brain connectivity differences were analyzed between mild cognitive impairment individuals with absent or low (n = 34) and high (n = 34) small vessel disease burden using data from the Parelsnoer Institute, a Dutch multicenter study. Small vessel disease was characterized using an ordinal scale considering: lacunes, microbleeds, perivascular spaces in the basal ganglia, and white matter hyperintensities. Resting state functional MRI data using 3 Tesla scanners was analyzed with group-independent component analysis using the CONN toolbox.

Results

Functional connectivity between areas of the cerebellum and between the cerebellum and the thalamus and caudate nucleus was higher in the absent or low small vessel disease group compared to the high small vessel disease group.

Conclusion

These findings might suggest that functional connectivity of mild cognitive impairment individuals with low or absent small vessel disease burden is more intact than in mild cognitive impairment individuals with high small vessel disease. These brain areas are mainly responsible for motor, attentional and executive functions, domains which in previous studies were found to be mostly associated with small vessel disease markers. Our results support findings on the involvement of the cerebellum in cognitive functioning.

Effects of proton therapy on regional [18F]FDG uptake in non-tumor brain regions of patients treated for head and neck cancer

Background and purpose

Previous pre-clinical research using [¹⁸F]FDG-PET has shown that whole-brain photon-based radiotherapy can affect brain glucose metabolism. This study, aimed to investigate how these findings translate into regional changes in brain [¹⁸F]FDG uptake in patients with head and neck cancer treated with intensity-modulated proton therapy (IMPT).

Materials and methods

Twenty-three head and neck cancer patients treated with IMPT and available [¹⁸F]FDG scans before and at 3 months follow-up were retrospectively evaluated. Regional assessment of the [¹⁸F]FDG standardized uptake value (SUV) parameters and radiation dose in the left (L) and right (R) hippocampi, L and R occipital lobes, cerebellum, temporal lobe, L and R parietal lobes and frontal lobe were evaluated to understand the relationship between regional changes in SUV metrics and radiation dose.

Results

Three months after IMPT, [¹⁸F]FDG brain uptake calculated using SUVmean and SUVmax, was significantly higher than that before IMPT. The absolute SUVmean after IMPT was significantly higher than before IMPT in seven regions of the brain (p ≤ 0.01), except for the R (p = 0.11) and L (p = 0.15) hippocampi. Absolute and relative changes were variably correlated with the regional maximum and mean doses received in most of the brain regions.

Conclusion

Our findings suggest that 3 months after completion of IMPT for head and neck cancer, significant increases in the uptake of [¹⁸F]FDG (reflected by SUVmean and SUVmax) can be detected in several individual key brain regions, and when evaluated jointly, it shows a negative correlation with the mean dose. Future studies are needed to assess whether and how these results could be used for the early identification of patients at risk for adverse cognitive effects of radiation doses in non-tumor tissues.

Effects of interventions on cerebral perfusion in the Alzheimer's disease spectrum: A systematic review

Cerebral perfusion dysfunctions are seen in the early stages of Alzheimer's disease (AD). We systematically reviewed the literature to investigate the effect of pharmacological and non-pharmacological interventions on cerebral hemodynamics in randomized controlled trials involving AD patients or Mild Cognitive Impairment (MCI) due to AD. Studies involving other dementia types were excluded. Data was searched in April 2021 on MEDLINE, Embase, and Web of Science. Risk of bias was assessed using Cochrane Risk of Bias Tool. A meta-synthesis was performed separating results from MCI and AD studies. 31 studies were included and involved 310 MCI and 792 CE patients. The MCI studies (n = 8) included physical, cognitive, dietary, and pharmacological interventions. The AD studies (n = 23) included pharmacological, physical interventions, and phytotherapy. Cerebral perfusion was assessed with PET, ASL, Doppler, fNIRS, DSC-MRI, Xe-CT, and SPECT. Randomization and allocation concealment methods and subject characteristics such as AD-onset, education, and ethnicity were missing in several papers. Positive effects on hemodynamics were seen in 75 % of the MCI studies, and 52 % of the AD studies. Inserting cerebral perfusion outcome measures, together with established AD biomarkers, is fundamental to target all disease mechanisms and understand the role of cerebral perfusion in AD.

Clinical relevance of the radiation dose bath in lower grade glioma, a cross-sectional pilot study on neurocognitive and radiological outcome

•

Radiation-induced brain damage as a consequence of the RT dose bath was investigated.

•

Multiple MRI-derived metrics and neurocognitive function domains were analysed.

•

Our novel approach accounted for confounding effects associated with lower grade glioma.

•

Higher RT dose to the left cerebrum was associated with poorer verbal memory performance.

•

Higher RT dose correlated with hippocampal volume.

Aim

To investigate the clinical relevance of the radiotherapy (RT) dose bath in patients treated for lower grade glioma (LGG).

Methods

Patients (n = 17) treated with RT for LGG were assessed with neurocognitive function (NCF) tests and structural Magnetic Resonance Imaging (MRI) and categorized in subgroups based on tumour lateralisation. RT dose, volumetric results and cerebral microbleed (CMB) number were extracted for contralateral cerebrum, contralateral hippocampus, and cerebellum. The RT clinical target volume (CTV) was included in the analysis as a surrogate for focal tumour and other treatment effects. The relationships between RT dose, CTV, NCF and radiological outcome were analysed per subgroup.

Results

The subgroup with left-sided tumours (n = 10) performed significantly lower on verbal tests. The RT dose to the right cerebrum, as well as CTV, were related to poorer performance on tests for processing speed, attention, and visuospatial abilities, and more CMB.

In the subgroup with right-sided tumours (n = 7), RT dose in the left cerebrum was related to lower verbal memory performance, (immediate and delayed recall, r = −0.821, p = 0.023 and r = −0.937, p = 0.002, respectively), and RT dose to the left hippocampus was related to hippocampal volume (r = −0.857, p = 0.014), without correlation between CTV and NCF.

Conclusion

By using a novel approach, we were able to investigate the clinical relevance of the RT dose bath in patients with LGG more specifically. We used combined MRI-derived and NCF outcome measures to assess radiation-induced brain damage, and observed potential RT effects on the left-sided brain resulting in lower verbal memory performance and hippocampus volume.

Role of Brain Imaging in Drug Development for Psychiatry

Background:

Over the last decades, many brain imaging studies have contributed to new insights in the pathogenesis of psychiatric disease. However, in spite of these developments, progress in the development of novel therapeutic drugs for prevalent psychiatric health conditions has been limited.

Objective:

In this review, we discuss translational, diagnostic and methodological issues that have hampered drug development in CNS disorders with a particular focus on psychiatry. The role of preclinical models is critically reviewed and opportunities for brain imaging in early stages of drug development using PET and fMRI are discussed. The role of PET and fMRI in drug development is reviewed emphasizing the need to engage in collaborations between industry, academia and phase I units.

Conclusion:

Brain imaging technology has revolutionized the study of psychiatric illnesses, and during the last decade, neuroimaging has provided valuable insights at different levels of analysis and brain organization, such as effective connectivity (anatomical), functional connectivity patterns and neurochemical information that may support both preclinical and clinical drug development. Since there is no unifying pathophysiological theory of individual psychiatric syndromes and since many symptoms cut across diagnostic boundaries, a new theoretical framework has been proposed that may help in defining new targets for treatment and thus enhance drug development in CNS diseases. In addition, it is argued that new proposals for data-mining and mathematical modelling as well as freely available databanks for neural network and neurochemical models of rodents combined with revised psychiatric classification will lead to new validated targets for drug development.

Abstract LB-297: Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy

Purpose: Traditional magnetic resonance imaging (MRI) of cancer in vivo is confounded by heterogeneous vessel architecture with stochastic perfusion. Here, we present a new imaging method coined as vessel architectural imaging (VAI), exploiting an overlooked temporal shift in the MRI signal used in vessel caliber estimation. We show that VAI identifies glioblastoma patients who respond to anti-VEGF therapy by improved microcirculation and prolonged survival [1].

Materials & Methods: In this IRB-approved phase II study of cediranib (NCT00305656), an oral pan-VEGF receptor kinase inhibitor [2], 30 patients with recurrent glioblastoma were imaged monthly during therapy, using a simultaneously acquired gradient-echo and spin-echo contrast enhanced perfusion MRI sequence for VAI [1]. When visualized in a scatter plot, the resulting point-by-point temporal gradient-echo and spin-echo tissue-concentration curves will form a vortex of a certain shape and traverse in a clockwise or counter-clockwise direction depending on tissue type. Typically, a clockwise vortex direction reflects the presence of smaller-caliber, fast-inflow arteriole vessels and capillaries only, whereas a counter-clockwise vortex direction is observed if the tissue also includes a larger-caliber, slow-inflow venule component. The vortex direction effect is attributed to the level of deoxygenated blood in the tissue and the corresponding size of the vortex area is proportional to the relative arteriole-to-venule oxygen saturation (SO2) levels of the tissue [1].

Results: Collectively, patients showed a significant increase in tumoral image voxels with a clockwise vortex direction during therapy (pair-wise Wilcoxons; P < 0.05), mimicking the direction ratios and vessel branching architecture of healthy tissue [1]. Ten responding patients, showing the biggest relative increase in image voxels with a clockwise vortex direction during therapy, also had reduced vessel calibers, improved SO2 levels and prolonged overall survival compared to 12 non-responders (341 days versus 146 days, Cox regression with time dependent covariates; P < 0.01) [1].

Discussion: Using VAI we were able to obtain novel information not provided by traditional MRI, including vessel architecture and SO2 levels. Our results indicate that VAI is a different and potentially more sensitive biomarker for anti-VEGF therapy response.

[1] Emblem KE et al. Nature Med. 2013; In press.

[2] Batchelor TT et al. J Clin Oncol. 2010; 28(17):2817-23.

Citation Format: Kyrre E. Emblem, Kim Mouridsen, Atle Bjornerud, Christian T. Farrar, Dominique Jennings, Ronald J.H Borra, Patrick Y. Wen, Percy Ivy, Tracy T. Batchelor, Bruce R. Rosen, Rakesh K. Jain, A. Gregory Sorensen. Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr LB-297. doi:10.1158/1538-7445.AM2013-LB-297

Voxelwise analysis of diffusion tensor imaging and structural MR imaging in patients with the m.3243A>G mutation in mitochondrial DNA

BACKGROUND AND PURPOSE

The m.3243A>G mutation is the most common pathogenic mutation in mtDNA; tissues with high dependence on aerobic energy metabolism, such as the brain, heart, and skeletal muscle, are most affected by the ensuing mitochondrial dysfunction. We hypothesized that the m.3243A>G mutation manifests as disturbances in white matter microstructural integrity and volumetric changes in the brain.

MATERIALS AND METHODS

DTI and structural MR imaging were performed on 15 adult patients with the m.3243A>G mutation and 14 healthy age-matched controls. Voxelwise analysis of the DTI data was performed to reveal possible differences in FA and MD values. Additionally, normalized brain tissue volumes of the subjects were measured, and voxelwise analysis of gray matter was performed to assess volumetric changes in the brain.

RESULTS

Among patients with m.3243A>G mutation, voxelwise analysis of the DTI data revealed significantly reduced FA in several areas located mainly in the occipital lobes, thalami, external and internal capsules, brain stem, cerebellar peduncles, and cerebellar white matter. There were no differences in MD values between the patients and the controls. Analysis of the structural MR imaging data revealed reduced total volume of gray and white matter in patients with m.3243A>G mutation, and VBM analysis identified areas of significant gray matter loss mainly in the occipital lobes and cerebellum.

CONCLUSIONS

Our findings show that patients with m.3243A>G mutation have mild microstructural damage leading to loss of directional organization of white matter and reduced brain volumes.